Abstract #2216

Combining Data from HR MAS MR Spectroscopy and Gene Expression Can Refine the Subclassification of Breast Cancer

Eldrid Borgan¹, Beathe Sitter², Tone Frost Bathen², Steinar Lundgren^2,3, Hilde Johnsen¹, Ole Christian Lingjrde⁴, Therese Srlie^1,4, Anne-Lise Brresen-Dale^1,5, Ingrid Susann Gribbestad²

¹Department of Genetics, Norwegian Radium Hospital, Rikshospitalet University Hospital, Oslo, Norway; ²Department of Circulation and Imaging, NTNU, Trondheim, Norway; ³Deptartment of Oncology, St. Olavs University Hospital, Trondheim, Norway; ⁴Department of Informatics, University of Oslo, Oslo, Norway; ⁵Faculty division, The Norwegian Radium Hospital, Faculty of Medicine, University of Oslo, Oslo, Norway

Joint analysis of gene expression microarrays and HR MAS metabolic profiles reveals differences within the luminal A tumors, a gene expression-based subtype of breast cancer. The luminal A subgroup is the largest and is associated with positive ER status and relatively good prognosis. However, a certain fraction of patients with luminal A breast cancer have a poor outcome. Preliminary results of 29 tumors from breast cancer patients show that differences in biochemistry and gene expression for two subgroups of luminal A tumors, identified by their metabolic MR profiles, are connected to lipid content and apoptosis.